Demand for therapeutic recombinant proteins will eventually exceed current production capabilities. This is a major driver in further understanding Chinese Hamster Ovary (CHO) cell biology, which is the cell line of choice for producing these proteins. Further R&D into CHO is expected to improve production capacity.
Would you like to access this CEP Article?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.